ADVANCED CANCER THERAPEUTICS - Key Persons
Job Titles:
- Chairman of the Board
- Founder
Dale J. Boden is a founder and Chairman of Advanced Cancer Therapeutics. He also serves as President and CEO of B F Capital, Inc., a Louisville, KY based private investment firm. Investing primarily in real estate, venture capital and early-stage or special situation growth companies, B F Capital provides both equity capital and management assistance.
Since founding B F Capital in 1993, Mr. Boden has overseen investments in more than 80 different companies and partnerships. In 2003, the Yearling Fund I, L.P. was formed by Mr. Boden and his two partners, Tyree Wilburn and William Lomicka. The Yearling Fund is an early stage venture capital fund focused on Kentucky-based companies. Mr. Boden serves on the boards of both public and private companies serving in varying capacities including Audit and Compensation Committee Chair, Lead Director and non-executive Chairman of the Board. Mr. Boden has profound experience in Corporate Development, M & A, Corporate Finance and General Management.
Dr. Donald M. Miller is a cofounder and Board Member for Advanced Cancer Therapeutics. He is the past Director of the James Graham Brown Cancer Center. He received his M.D. and Ph.D. from Duke University, trained in Internal Medicine at the Peter Bent Brigham Hospital at Harvard University. Dr. Miller did his Oncology training and a research fellowship at the National Cancer Institute. He has been on the faculty at the University of Michigan and the University of Alabama at Birmingham, prior to coming to Louisville. Over the past 15 years, the Brown Cancer Center (BCC) has developed a nationally recognized research program in cancer drug development with more than a two dozen novel treatments being studied in their labs, with numerous entering early phase clinical trials. The unique strengths of BCC scientists have led to the formation of Advanced Cancer Therapeutics (ACT), a University/private investor partnership to develop novel therapeutics from the Brown Cancer Center labs.
R. Ted Steinbock, M.D. is a practicing radiologist and President of X-Ray Associates of Louisville PSC with a distinguished career of service to patients, organizations, and the community. Dr. Steinbock has twice been awarded the Louisville Top Doctor award by the Greater Louisville Medical Society. He is on the Board of Directors of the James Graham Brown Foundation, has held academic positions in radiology at Harvard University, the University of New Mexico, and the University of Louisville, and he serves in advisory roles to numerous entrepreneurial companies including medical device and personalized medicine companies. Dr. Steinbock consults with several organizations in the areas of imaging utilization, risk management, and procedure reimbursement. He is also an avid book collector and published expert in the field of paleopathology.
Dr. Steinbock is on the Radiology Council for the American Heart Association, is part of the Society for Cardiovascular and Interventional Radiology (SCVIR), and served for twelve years as the Chairman of Radiology for Baptist Hospital East. Dr. Steinbock graduated AB Magna cum laude with Highest Honors from Harvard University and MD Magna cum laude from Harvard Medical School, and completed his Radiology Residency at Massachusetts General Hospital. He is Board Certified by the American Board of Radiology, licensed to practice medicine in Kentucky, and currently maintains privileges in diagnostic radiology at Baptist Hospital East in Louisville, Kentucky.
Randall B. Riggs joined ACT with over fifteen years of corporate strategy and business development experience within the pharmaceutical and biotechnology industries. From 2005 to October of 2007 he was the Senior Vice President of Corporate Development for BioCryst Pharmaceuticals and was responsible for approximately $1 billion dollars in strategic partnerships with multi-national firms including Hoffman-La Roche, Shionogi & Co., Mundipharma International LTD, and Green Cross Corp. Prior to BioCryst Pharmaceuticals, Mr. Riggs held the position of Senior Vice President of Corporate Development for Lexicon Pharmaceuticals (1998 - 2004). As a member of the Executive Management Team, over $200 million was raised through their initial public offering in April 2000. In addition to his key role in Lexicon's successful IPO, Mr. Riggs oversaw an increase in strategic partnership revenue from less than $2 million to over $60 million each year.
Mr. Riggs began his career in the pharmaceutical industry at Eli Lilly & Company in 1992 in sales and sales management, and was quickly promoted to Manager in Corporate Business Development at corporate headquarters in Indianapolis. During this time he played a leading role in the evaluation of several strategic acquisitions, product in-licensing opportunities, and establishment of several collaborations with biotechnology companies. A member of the Licensing Executive Society (LES), Mr. Riggs was elected in 2007 as the President of the Biotechnology Association of Alabama (BAA) in Birmingham, Alabama. Mr. Riggs received his Bachelor of Business Administration (BBA) in Management with honors cum laude from Texas A&M University and his Masters in Business Administration (MBA) in Finance from the University of Houston.
Robert W. Rounsavall, III is Manager of Dixie Real Properties, LLC, a Louisville based industrial real estate development and management company. He currently serves as a board member for the Regional Cancer Center Corporation, an oversight and advisory board for the Brown Cancer Center; the University of Louisville Board of Trustees, University of Louisville Board of Overseers; KentuckyOne Health Board of Directors.
Mr. Rounsavall previously served on the board of Louisville-based cancer drug development company Aptamera, Inc. from 2003 until the company's acquisition in 2005 by UK-based Antisoma plc. Aptamera was co-founded by Dr. Don Miller, Director of the University of Louisville's Brown Cancer Center, to discover, develop and commercialize new anti-cancer drugs.
Job Titles:
- Co - Founder
- Member of the Board
In addition to being a co-founder and Board Member of Advanced Cancer Therapeutics, Ty Wilburn is a general partner and cofounder of the Yearling Funds, venture capital funds focused on early stage companies. He is also a director of a number of companies (both public and private) and community organizations. From 2002 to 2012, Mr. Wilburn was Chairman and CEO of Merit Health Systems, a private equity backed owner and operator of urban community hospitals. Merit was sold in 2012 providing a substantial return to its investors. For six years prior to Merit Mr. Wilburn actively invested his personal
capital in a number of early stage companies, often taking a board seat. During this time Mr. Wilburn was the founding Chairman of Aptamera, a cancer drug development company formed out of the Brown Cancer Center at the University of Louisville. As Chairman and initial investor, he raised the seed funding for the company, helped with subsequent fund raising, helped form a board of directors, and assisted in the company's development. Aptamera was sold in 2005 for approximately four times the company's paid-in capital.
In the early 90's Mr. Wilburn joined Community Health Systems, a small young hospital company in Nashville. During a five year span, he helped grow Community into a major player in the industry; taking it to the New York Stock Exchange and, as CEO-elect, led the very successful go-private sale of the company to Forstmann Little and Company. Prior to Community Health Systems, Mr. Wilburn spent eighteen years at Humana in various senior positions.